Elevance Health (NYSE:ELV) Issues FY 2025 Earnings Guidance

Key Points

• Elevance Health has issued its FY 2025 earnings guidance, projecting earnings per share (EPS) of $30.00, higher than the consensus estimate of $29.88.
• The company reported quarterly earnings of $8.84 per share, missing analysts' estimates of $9.30, despite a year-over-year revenue increase of 14.3% to $49.42 billion.
• Elevance Health's quarterly dividend of $1.71 will be paid to stockholders on September 25th, representing an annualized yield of 2.2% and a payout ratio of 29.11%.

Elevance Health (NYSE:ELV - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 30.000-30.000 for the period, compared to the consensus estimate of 29.880. The company issued revenue guidance of -.

Elevance Health Stock Performance

NYSE ELV traded down $8.11 during mid-day trading on Thursday, reaching $313.48. 644,218 shares of the stock were exchanged, compared to its average volume of 1,963,164. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The business's 50 day moving average is $314.70 and its 200-day moving average is $374.49. The company has a market capitalization of $70.59 billion, a P/E ratio of 13.31, a P/E/G ratio of 1.17 and a beta of 0.59. Elevance Health has a 1 year low of $273.71 and a 1 year high of $559.95.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share for the quarter, missing analysts' consensus estimates of $9.30 by ($0.46). The company had revenue of $49.42 billion for the quarter, compared to analyst estimates of $48.26 billion. Elevance Health had a return on equity of 17.59% and a net margin of 2.83%.The business's revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $10.12 earnings per share. On average, equities research analysts forecast that Elevance Health will post 33.96 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Wednesday, September 10th will be given a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 10th. Elevance Health's dividend payout ratio is 29.11%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ELV shares. Morgan Stanley reduced their target price on shares of Elevance Health from $428.00 to $316.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. Barclays reissued an "overweight" rating on shares of Elevance Health in a report on Thursday. Royal Bank Of Canada reissued an "outperform" rating and issued a $478.00 price objective on shares of Elevance Health in a report on Wednesday, June 4th. Argus reissued a "hold" rating on shares of Elevance Health in a report on Monday, July 21st. Finally, UBS Group reiterated a "buy" rating and issued a $484.00 price objective (down from $555.00) on shares of Elevance Health in a research report on Monday, July 14th. Twelve investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $413.81.

Insider Activity at Elevance Health

In other Elevance Health news, Director Susan D. Devore acquired 1,200 shares of the stock in a transaction dated Tuesday, August 19th. The stock was acquired at an average price of $312.15 per share, with a total value of $374,580.00. Following the completion of the purchase, the director owned 3,502 shares in the company, valued at $1,093,149.30. This trade represents a 52.13% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Gail Boudreaux acquired 8,500 shares of the stock in a transaction dated Friday, July 18th. The stock was acquired at an average cost of $286.94 per share, with a total value of $2,438,990.00. Following the purchase, the chief executive officer owned 151,020 shares of the company's stock, valued at approximately $43,333,678.80. This trade represents a 5.96% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in Elevance Health in the second quarter worth approximately $127,000. Transamerica Financial Advisors LLC lifted its stake in Elevance Health by 43.9% in the second quarter. Transamerica Financial Advisors LLC now owns 616 shares of the company's stock worth $239,000 after acquiring an additional 188 shares during the last quarter. MUFG Securities EMEA plc purchased a new position in Elevance Health in the second quarter worth approximately $260,000. Kestra Investment Management LLC lifted its stake in Elevance Health by 20.8% in the second quarter. Kestra Investment Management LLC now owns 709 shares of the company's stock worth $276,000 after acquiring an additional 122 shares during the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in Elevance Health in the second quarter worth approximately $363,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.